Limitations and pitfalls of Tc-99m-EDDA//HYNIC-TOC (Tektrotyd) scintigraphy

被引：21

作者：

Garai, Ildiko ^{[1
,2
]}

Barna, Sandor ^{[1
]}

Nagy, Gabor ^{[1
]}

Forgacs, Attila ^{[1
]}

机构：

[1] ScanoMed Ltd, Debrecen, Hungary

[2] Univ Debrecen, Dept Diagnost Imaging, Debrecen, Hungary

来源：

NUCLEAR MEDICINE REVIEW | 2016年 / 19卷 / 02期

关键词：

somatostatin receptor scintigraphy; Tc-99m-EDDA/HYNIC-Tyr3-octreotide; pitfalls;

D O I：

10.5603/NMR.2016.0019

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Tektrotyd kit was developed by Polatom company for Tc-99m labeling to make an alternative tracer of somatostatin receptor scintigraphy available. Since 2005, Tc-99m-EDDA/HYNIC-Tyr(3)-Octreotide has been used in clinical imaging and achieved high impact in management of patients with neuroendocrine tumors. Knowing the limitations and pitfalls is essential to provide accurate diagnosis. Therefore, the potential pitfalls associated with the use of Tc-99m-EDDA/HYNIC-TOC are reviewed on the basis of own experience. Data were analyzed of 310 patients who underwent somatostatin receptor scintigraphy with Tc-99m-Tektrotyd. Pitfalls during radiolabeling process or acquisition can worsen the sensitivity of SRS (somatostatin receptor scintigraphy). Recognizing physiological and clinical pitfalls, the diagnostic accuracy will improve.

引用

页码：93 / 98

页数：6

共 13 条

[1]

Artiko V, 2012, J BUON, V17, P537

[2] Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide:: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide [J].

Bangard, M ;

Béhé, M ;

Guhlke, S ;

Otte, R ;

Bender, H ;

Maecke, HR ;

Biersack, HJ .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (06) :628-637

[3]

Barbieri F, 2013, INT J PEPT, V2013

[4]

Callison J Clay Jr, 2011, J Lung Cancer, V10, P69

[5] 99mTc-EDDA/HYNIC-TOC:: a new 99Tc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours:: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives [J].

Decristoforo, C ;

Mather, SJ ;

Cholewinski, W ;

Donnemiller, E ;

Riccabona, G ;

Moncayo, R .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (09) :1318-1325

[6] Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits [J].

Gonzalez-Vazquez, Armando ;

Ferro-Flores, Guillermina ;

Arteaga De Murphy, Consuelo ;

Gutierrez-Garcia, Zohar .

APPLIED RADIATION AND ISOTOPES, 2006, 64 (07) :792-797

[7] SOMATOSTATIN RECEPTOR SCINTIGRAPHY WITH [IN-111-DTPA-D-PHE(1)]- AND [I-123-TYR(3)]-OCTREOTIDE - THE ROTTERDAM EXPERIENCE WITH MORE THAN 1000 PATIENTS [J].

KRENNING, EP ;

KWEKKEBOOM, DJ ;

BAKKER, WH ;

BREEMAN, WAP ;

KOOIJ, PPM ;

OEI, HY ;

VANHAGEN, M ;

POSTEMA, PTE ;

DEJONG, M ;

REUBI, JC ;

VISSER, TJ ;

REIJS, AEM ;

HOFLAND, LJ ;

KOPER, JW ;

LAMBERTS, SWJ .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1993, 20 (08) :716-731

[8]

Kunikowska J, 2016, J NUCL MED, V57

[9]

MACKIE EJ, 1990, DEVELOPMENT, V110, P1233

[10] Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors [J].

Modlin, Irvin M. ;

Moss, Steven F. ;

Chung, Daniel C. ;

Jensen, Robert T. ;

Snyderwine, Elizabeth .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (18) :1282-1289

← 1 2 →